Transarterial therapies for primary liver tumors

Adam D Talenfeld; Akhilesh K Sista; David C Madoff

doi:10.1016/j.soc.2013.11.002

Transarterial therapies for primary liver tumors

Surg Oncol Clin N Am. 2014 Apr;23(2):323-51. doi: 10.1016/j.soc.2013.11.002.

Authors

Adam D Talenfeld¹, Akhilesh K Sista¹, David C Madoff²

Affiliations

¹ Division of Interventional Radiology, Department of Radiology, New York-Presbyterian Hospital/Weill Cornell Medical Center, 525 East 68th Street, New York, NY 10065, USA.
² Division of Interventional Radiology, Department of Radiology, New York-Presbyterian Hospital/Weill Cornell Medical Center, 525 East 68th Street, New York, NY 10065, USA. Electronic address: dcm9006@med.cornell.edu.

PMID: 24560113
DOI: 10.1016/j.soc.2013.11.002

Abstract

Over the last decade, transarterial therapies have gained worldwide acceptance as standard of care for inoperable primary liver cancer. Survival times after transarterial chemoembolization (TACE) continue to improve as the technique and selection criteria are refined. Transarterial treatments, frequently provided in an outpatient setting, are now safely and effectively being applied to patients with even advanced malignancy or partially decompensated cirrhosis. In the coming years, newer transarterial therapies such as radiation segmentectomy, boosted-transarterial radioembolzation, combined TACE-ablation, TACE-portal vein embolization, and transarterial infusion of cancer-specific metabolic inhibitors promise to continue improving survival and quality of life.

Keywords: Chemoembolization; Cholangiocarcinoma; Hepatocellular carcinoma; Radioembolization; Transarterial.

Publication types

Review

MeSH terms

Antineoplastic Agents / administration & dosage*
Carcinoma, Hepatocellular / therapy*
Embolization, Therapeutic / methods*
Humans
Infusions, Intra-Arterial
Liver Neoplasms / therapy*

Substances

Antineoplastic Agents